David Moller has joined Sigilon Therapeutics to become the company’s chief scientific officer. Moller comes to the Cambridge, MA, drug developer from Eli Lilly (NYSE: LLY), where he was vice president of business development for emerging technology and innovation. Last year, Sigilon raised $23.5 million in a Series A financing round to bring its technology for encapsulating therapeutic proteins into clinical testing.
Sponsored · Whitepaper
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health Sciences
From Our Editors · Special Report
Top biotech and investment players offer their best plans and current progress in stemming and ultimately defeating the worldwide pandemic
Sponsored · Webinar
A discussion on business drivers, technical considerations, special requirements of cell and gene product manufacturing & digitization strategy
Global OT/IT Quality Services
